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HIV-1 Nef has the ability to downmodulate CD4 cell surface expression. Several studies have shown that CD4 downregulation is required for
efficient virus replication and high infectivity. However, the pathophysiological relevance of this phenomenon in vivo, independently of its role in
sustaining high virus loads, remains unclear. We studied the impact of the CD4 downregulation function of Nef on its pathogenesis in vivo, in the
absence of viral replication, in the CD4C/HIV transgenic (Tg) mouse model. Two independent Nef mutants (RD35/36AA and D174K), known to
abrogate CD4 downregulation, were tested in Tg mice. Flow cytometry analysis showed that downregulation of murine CD4 was severely
decreased or abrogated on Tg T cells expressing respectively NefRD35/36AA and NefD174K. Similarly, the severe depletion of double-positive
CD4+CD8+ and of single-positive CD4+CD8 thymocytes, usually observed with NefWt, was not detected in NefRD35/36AA and NefD174K Tg
mice. However, both mutant Tg mice showed a partial depletion of peripheral CD4+ T cells. This was accompanied, as previously reported for
NetWt Tg mice, by the presence of an activated/memory-like phenotype (CD69+, CD25+, CD44+, CD45RBLow, CD62Low) of CD4+ T cells
expressing NefRD35/36AA and to a lesser extent NefD174K. In addition, both mutants retained the ability to block CD4+ T cell proliferation in vitro
after anti-CD3 stimulation, but not to enhance apoptosis/death of CD4+ T cells. Therefore, it appears that Nef-mediated CD4 downregulation is
associated with thymic defects, but segregates independently of the activated/memory-like phenotype, of the partial depletion and of the impaired
in vitro proliferation of peripheral CD4+ T cells. Histopathological assessment revealed the total absence of or decrease severity and frequency of
organ AIDS-like diseases (lung, heart and kidney pathologies) in respectively NefRD35/36AA and NefD174K Tg mice, relative to those developing in
NefWt Tg mice. Our data suggest that the RD35/36AA and D174K mutations affect other Nef functions, namely those involved in the
development of lung and kidney diseases, in addition to their known role in CD4 downregulation. Similarly, in HIV-1-infected individuals, loss of
CD4 downregulation by Nef alleles may reflect their lower intrinsic pathogenicity, independently of their effects on virus replication.
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Nef is one of three HIV proteins (with Env and Vpu)
responsible for the downregulation of the CD4 cell surface
expression (reviewed in Piguet et al., 1999; Lama, 2003). Nef
functions early and favors the internalization of CD4
molecules already present on the cell surface (Aiken et al.,0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.10.010
* Corresponding author. Clinical Research Institute of Montreal, 110 Pine
Avenue West, Montreal, Quebec, Canada H2W 1R7. Fax: +1 514 987 5794.
E-mail address: Zaher.Hanna@ircm.qc.ca (Z. Hanna).1994; Chen et al., 1996; Rhee and Marsh, 1994; Guy et al.,
1987; Garcia and Miller, 1991; Anderson et al., 1993;
Mariani and Skowronski, 1993). This process involves the
recruitment by Nef of cellular factors, notably the adaptor
protein complexes (AP-1, AP-2 and AP-3) of clathrin-coated
pits (Mangasarian et al., 1999; Foti et al., 1997; Greenberg et
al., 1997; Piguet et al., 1998; Craig et al., 1998) and NBP1, a
protein homologous to the catalytic subunit of a yeast
vacuolar ATPase (Lu et al., 1998). This complex then binds
to a dileucine motif in the cytoplasmic tail of CD4 (Aiken et
al., 1994; Anderson et al., 1994; Craig et al., 1998) and
directs it to lysosomes for degradation through a Nef06) 40 – 52
www.e
Z. Hanna et al. / Virology 346 (2006) 40–52 41dileucine motif acting as a lysosomal targeting signal (Aiken
et al., 1994; Greenberg et al., 1997; Piguet et al., 1998; Craig
et al., 1998; Rhee and Marsh, 1994).
In vitro studies have provided insights into the role of Nef-
mediated CD4 downregulation in HIV-1 viral production and
infectivity (reviewed in Piguet et al., 1999; Lama, 2003).
Downregulation of CD4 expression by Nef was shown to
prevent superinfection and to enhance HIV-1 replication
(reviewed in Cullen, 1994; Guatelli, 1997; Harris, 1999). In
addition, recent findings have shown that the downregulation
of CD4 may have an additional positive effect on HIV
infectivity. These studies showed that increased level of CD4
expression on cell surface interferes with infectivity and viral
particle release (Bour et al., 1999; Lama et al., 1999; Arganaraz
et al., 2003; Lundquist et al., 2004; Ross et al., 1999). Removal
of CD4 cell surface, by nonmembrane-bound and membrane-
bound form (Alexander et al., 2004) of Nef appears to prevent
virion incorporation of CD4 and facilitate the Env incorpora-
tion into HIV-1 or SIV particles, leading to enhancement of
viral infectivity and viral replication, including in PBMC
(Arganaraz et al., 2003; Glushakova et al., 2001; Stoddart et
al., 2003; Lundquist et al., 2002; Patel et al., 2002; Carl et al.,
2001).
Moreover, experiments in vivo have also suggested that
CD4 downregulation may influence HIV and SIV pathogene-
sis. Macaques infected with an SIV strain that contains a
mutation in Nef domains known to disrupt its ability to
downregulate CD4 had strong reduction of viral loads and were
largely protected from disease until these mutations reverted to
restore CD4 downregulation function and pathogenicity
(Iafrate et al., 2000). Also, Nef alleles isolated at later stages
of HIV-1 or SIV infection and progression to AIDS showed
increased ability to downregulate CD4 relative to those isolated
from long-term nonprogressors (LTNP) or early asymptomatic/
slow progressors (Patel et al., 2002; Tobiume et al., 2002;
Arganaraz et al., 2003; Carl et al., 2001; Casartelli et al., 2003;
Mariani et al., 1996).
The above studies strongly argue for the importance of Nef-
mediated CD4 downregulation in facilitating increased release
and spread of HIV in vivo with the consequent establishment of
high virus loads and pathogenicity (Piguet et al., 1999; Lama,
2003; Cullen, 1994; Guatelli, 1997; Harris, 1999). However, a
role of the Nef-mediated CD4 downregulation function on viral
pathogenicity independent of its role on viral replication/
infectivity could not be evaluated in these studies. For example,
such perturbations could include impairment of T cell selection,
of CD4+ helper T cell functions or of T cell receptor (TCR)
signaling. In particular, CD4 downregulation may affect the
transduction of signals produced from engagement of CD4 on
the surface of the infected cells. Indeed, the strength of CD4
contact with a ligand has been shown to be critical for immune
responses, and for T cell differentiation (see for example Frank
and Parnes, 1998).
It is already known from Tg animal models that Nef harbors
major determinants of pathogenicity which are totally inde-
pendent of virus replication (Skowronski et al., 1993; Brady et
al., 1993; Lindemann et al., 1994; Hanna et al., 1998b). Inparticular, our laboratory has shown that Nef can induce a
severe AIDS-like disease when expressed under the control of
the CD4C promoter comprising the regulatory sequences of the
human CD4 gene fused to the murine CD4 enhancer (Hanna et
al., 1998b). Thus, the goal of the present work was to assess
whether CD4 downregulation, known to occur in murine cells
expressing wild-type Nef (NefWt) (Anderson et al., 1993;
Skowronski et al., 1993; Brady et al., 1993; Hanna et al.,
1998b), has a direct impact on Nef pathogenicity independently
from its role in viral replication. Several investigators have
identified multiple Nef residues which are involved in CD4
downregulation: R25, RD35/36, T80, GL96/97, D108, D111,
DW123/124, RY134/135, C142, EE154/155, LL164/165,
DD174/175, RRE179, RF184/185 (Hua and Cullen, 1997;
Hua et al., 1997; Aiken et al., 1996; Iafrate et al., 1997). We
selected two of these mutants (NefRD35/36AA and NefD174K),
impaired in their ability to downregulate CD4, for our in vivo
study. Previous in vitro work with human cells has established
that mutations at residues 35/36 (arginine-aspartic acid) or at
residue 174 (aspartic acid) of Nef selectively abrogated its CD4
downregulation function without affecting its other functions,
such as its ability to block anti-CD3 stimulation, to activate
CD69 expression, to downmodulate MHC class I molecule or to
stimulate virus replication (Aiken et al., 1996; Stoddart et al.,
2003; Iafrate et al., 1997; Lundquist et al., 2002; Mangasarian et
al., 1999) (reviewed in Zuniga et al., 2004). The NefRD35/36AA
and NefD174K mutants were expressed in Tg mice under the
control of the CD4C promoter used before. Our results reveal
that these two mutations have major negative impacts on the in
vivo pathogenicity of Nef in this Tg model.
Results
Generation of CD4C/HIV-Nef mutant Tg mice
To investigate the role CD4 downregulation on HIV-1 Nef-
induced pathogenesis in vivo, we constructed two indepen-
dent Nef transgenes, mutated at amino acid residues that were
previously shown to affect this function in human cells in
vitro (Aiken et al., 1996; Janvier et al., 2001; Stoddart et al.,
2003; Greenberg et al., 1997; Iafrate et al., 1997; Lundquist et
al., 2002; Mangasarian et al., 1999). The arginine/aspartic
acid at position 35/36 and aspartic acid at position 174 of
HIV-1 Nef (strain NL4-3) were mutated by site-directed
mutagenesis to alanines (RD35/36AA) and lysine (D174K),
respectively. These mutated Nef alleles were then recombined
with the CD4C/HIVMutG cassette, replacing the wild-type Nef
(NefWt), to generate the corresponding transgenes, CD4C/
HIV-NefRD35/36AA (NefRD35/36AA) and CD4C/HIV-NefD174K
(NefD174K) (Fig. 1A). The CD4C regulatory elements used in
these constructs have previously been shown to promote
expression of surrogate genes, including HIV-1 Nef, in CD4+
T cells and cells of monocyte/macrophage and dendritic
lineages of Tg mice (Hanna et al., 1994, 1998b, 1998a,
2001a). These cell populations are the major natural target
cells for HIV-1 infection in humans. In these CD4C/HIV-Nef
constructs, all the known open reading frames (ORF) of HIV-
Fig. 1. Construction and expression analysis of the CD4C/HIV-NefMut Tg mouse. (A) Diagram of the CD4C/HIV-NefRD35/36AA and CD4C/HIV-NefD174K
transgenes. Construction of these two transgenes is described in Materials and methods. Symbols: mCD4enh, mouse CD4 enhancer; hCD4 prom, human CD4
promoter; SV40, polyadenylation sequences from SV40; Ex1, CD4 gene exon1; X represents interruption of the ORF of the indicated HIV-1 gene. Restriction sites:
A, AatII; Bs, BssHII; S, SstI. (B) Northern blot analysis of HIV-1 RNA. Various tissues from different founder (F) lines of each of the CD4C/HIV-NefMut transgene
were analyzed. Total RNAs were hybridized with 32P-labeled HIV-1-specific probes. Symbols: T, thymus; S, spleen; L, lymph nodes; K, kidney. (C) Transgene
expression in sorted CD4+ T cells from pLN. Expression was evaluated by RT-PCR. (D) Western blot analysis of protein extracts from thymuses from 1-month-old
Tg and non-Tg littermates from different founders using rabbit anti-Nef antibodies. Thymuses from CD4C/HIVMutG Tg mice (F27367, high expresser and F27372,
low expresser) were used as a positive control.
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1998b). At least two expresser Tg founder (F) lines were
generated for each Nef mutant (NefRD35/36AA: F62327,
F62328; NefD174K: F61270, F81526, F81527). Tg lines were
maintained by breeding on the C3H background.
As expected from our early work (Hanna et al., 1998a,
1998b), Northern blot analysis on tissues from different organs
revealed the presence of the three main HIV-1 RNA transcripts
principally expressed in lymphoid tissues (thymus, spleen and
lymph nodes (LN)) and to a lesser extent in kidney (Fig. 1B)
and lung (data not shown). Expression was not detected in
other organs (liver, heart, brain, skin) (data not shown). The
strength of the RNA signal correlates with the number of target
cells for Nef expression (CD4+ T cells, macrophages, dendritic
cells (DC)) present in each organ, the highest expression being
in the thymus, as expected.
To further confirm expression of mutated Nef in peripheral
CD4+ T cells, Tg RNA levels were measured on pLN sorted
CD4+ T cells (>97% pure) by RT-PCR. This analysis showed
that expression of RNA in NefRD35/36AA and NefD174K Tg LN
CD4+ T cells was comparable to that in NefWt Tg mice (Fig.
1C). Consistent with the Northern blot data, Western immu-
noblot analysis with anti-Nef antiserum detected Nef protein
expression in the same lymphoid tissues (Fig. 1D, data not
shown). Thus, this expression pattern reflects the specificity of
the CD4C promoter previously documented (Hanna et al.,
1994, 1998a, 1998b, 2001a). However, as expected from
previous studies, the level of expression varied among different
Tg founder lines, most likely as a result of difference in the
integration sites of the transgene. We selected Tg lines
expressing the mutated Nef proteins at levels comparable to
wild-type (CD4C/HIV-NefWt) for comparative studies. Mice
from two founder lines of NefRD35/36AA Tg mice expressed the
transgene at levels almost equal to those of NefWt Tg mice,
while mice from the NefD174K Tg lines expressed it at lower
(F81526, F81527) or at significantly higher (5 X) (F61270)
levels than those of NefWt Tg mice (Fig. 1B). Thus, levels of
expression of Nef in different founder lines were: for CD4C/
HIV-NefRD35/36AA, F62328 > F62327; for CD4C/HIV-
NefD174K, F61270 > F81527 > F81526.
Abrogation or development of a milder AIDS-like disease in Tg
mice expressing Nef DR35/36AA or Nef D174K allele
The life span and death of Tg mice expressing NefWt are
largely dependent on the severity of the kidney and lung diseases
(Hanna et al., 1998b). Tg mice expressing NefRD35/36AA or
NefD174K survived in apparent good health during the course of
this study (16 months), in contrast to Tg mice expressing wild-
type Nef (Fig. 2A). The life span of NefRD35/36AA and NefD174K
Tgmice was almost comparable to that of non-Tgmice, as only a
few mortalities occurred in each group.
Further histological evaluation of tissues from both founders
of the NefRD35/36AA Tg mice at different ages (6–14 months
old) showed undistinguishable appearance from that of non-Tg
mice littermates, except for some disorganization of thymuses
(not shown) and follicular hyperplasia in LN in some animals(Fig. 2B). In particular, NefRD35/36AA-expressing Tg mice
showed no obvious depletion of lymphocytes on histological
sections of peripheral LN and spleen, nor any Tg-specific
changes in the lung, heart and kidneys (Fig. 2B, and data not
shown).
However, NefD174K Tg mice from the very high expresser
founder (F61270) showed typical, Tg-specific pathologies
similar to those observed previously in NefWt Tg studies
(Hanna et al., 1998a, 1998b, 2004; Kay et al., 2002).
However, these pathological changes were milder than in
NefWt-expressing mice considering the high levels of
transgene expression in this founder. These include disorga-
nization of thymuses (7/8 Tg and 0/4 non-Tg), changes in
the LN architecture (follicular hyperplasia, involution, fibro-
sis) (3/8 Tg and 0/5 non-Tg), focal segmental glomerulo-
sclerosis (FSGS) and tubulo-interstitial nephritis with
microcystic tubular dilatation in the kidney (5/8 Tg and 0/
9 non-Tg), lymphocytic interstitial pneumonitis (LIP) in the
lungs (2/8 Tg and 0/9 non-Tg) and focal myocytolysis
associated by fibrosis in the heart (1/8 Tg and 0/9 non-Tg)
(Fig. 2B and data not shown). NefD174K Tg mice from the
founder lines F81526 and F81527 also showed some of the
phenotypes at low frequency, despite their low expression:
cardiac disease (3/25 Tg and 1/18 non-Tg), lung disease
(LIP) (2/15 Tg and 1/18 non-Tg), LN changes (11/25 Tg and
3/18 non-Tg) and thymic atrophy (7/23 Tg and 0/12 non-
Tg). A summary of the phenotypes observed in these Tg
mice is shown in Table 1.
These results show that these mutations have not only
disrupted the ability of Nef to downregulate CD4 (see below),
but also had dramatically impaired its capacity to induce a
lethal AIDS-like disease in Tg mice.
Downregulation of murine CD4 cell surface expression is
decreased or abrogated on Tg lymphoid T cells expressing
Nef RD35/36AA or Nef D174K
We previously showed that NefWt is quite effective at
downregulating the cell surface expression of murine CD4 on T
cells of Tg mice (Hanna et al., 1998a, 1998b). To examine the
capacity of NefD174K and NefRD35/36AA alleles at downregulat-
ing the murine CD4 cell surface expression, a FACS analysis
was carried out on thymocytes and on cells from peripheral
lymphoid organs (spleen, LN). This analysis showed that the
mean fluorescence intensity of CD4 expression was not
decreased on NefD174K-expressing thymocytes (Fig. 3A, Table
2) and on cells of peripheral lymphoid organs (Fig. 3B, Table
3) and was comparable to that of non-Tg mice. In CD4C/HIV-
NefRD35/36AA Tg mice, a minor (12–22%) CD4 downregula-
tion was observed on thymocytes (Fig. 3A, Table 2) and on
peripheral CD4+ T cells (Fig. 3B, Table 3). Although this
downregulation did not reach statistical significance, it was
easily noticeable in many Tg mice.
These results indicated that the RD35/36AA, and to a
larger extent the D174K mutations of HIV-1 Nef abrogate
downregulation of murine CD4 as efficiently as that of human
CD4.
Fig. 2. Absence or less severe AIDS-like disease in respectively CD4C/HIV-NefRD35/36AA and CD4C/HIV-NefD174K Tg mice. (A) Survival of CD4C/HIV-NefMut Tg
and their littermate controls. The cumulative incidences of mortality were plotted as percentage of surviving mice. NefWt represents the CD4C/HIVMutG (F27367) Tg
mice used as positive controls. (B) Histopathology observed onH&E-stained paraffin sections of organs fromTgmice expressingNefRD35/36AA (F62328) andNefD174K
(F61270) or NefWt. (a) Non-Tg LN; (b) Follicular hyperplasia in CD4C/HIV-NefRD35/36AATg mice; (c) Kidney shows no pathology in CD4C/HIV-NefRD35/36AATg
mice; (e) Lymphocytic interstitial pneumonitis in CD4C/HIV-NefD174K Tg mice, as compared with the non-Tg normal lung (d); (f) Atrophic LN in CD4C/HIV-
NefD174K Tg mice; (g) Kidney disease in CD4C/HIV-NefD174K Tg mice showing FSGS and tubular changes. For comparison, lymphocytic interstitial pneumonitis (h),
atrophic LN (i) and kidney disease (FSGS and tubular changes) (j) in CD4C/HIV-NefWt Tg mice are shown. Magnification: a, b, f, i: 2.5; d, e, h: 20; c, g, j: 40.
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Table 1
Summary of the phenotypes observed in CD4C/HIVNef mutants Tg mice
Nef mutation Nef expression Non-lymphoid organ diseasea CD4 downregulation (%)b CD4+ T cell depletion (%)b
LIP Nephropathy Thy LN Thy LN
WT 1 0.68 0.67 68 61 83 71
RD35/36AA 1 NDc ND 22 21 0 35
D174K 5 0.25 0.87 0 12 20 49
a A mean score was calculated for all mice of the group, as described in Materials and methods.
b Percentage was calculated relative to non-Tg control mice. The data shown are for the founder lines expressing the highest levels of the Nef mutants (NefRD35/36AA,
F62328; NefD174K, F61270).
c ND, no disease.
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largely prevented in CD4C/HIV-Nef RD35/36AA and
CD4C/HIV-Nef D174K Tg mice
To further characterize the status of various lymphocyte
populations, cells from lymphoid organs (thymus, spleen, LN)
of Nef mutant Tg mice and of their control non-Tg littermates
were stained with fluorescently labeled antibodies specific for
different T- (CD4, CD8, Thy-1, TcRah), B- (B220) lymphocyte
and macrophage (Mac-1) cell surface markers and analyzed by
flow cytometry. This analysis showed that the total number of
thymocytes (Table 4) as well as the major thymocyte sub-
populations (double-positive CD4+CD8+ and single-positive
CD4+CD8, CD4CD8+ T cells; Fig. 3A, Table 2) from
NefRD35/36AA and NefD174K Tg mice were comparable to that
of their non-Tg littermates. Similarly, the total cell numbers in
peripheral organs did not vary significantly between Tg and non-
Tgmice (Table 4). However, in NefRD35/36AATgmice, there was
amoderate but significant depletion of mature CD4+ Tcells from
the peripheral organs (Table 3). Such depletion of peripheral
CD4+ Tcells was not observed in two founder lines of NefD174K
Tgmice (F81526, F81527), but could be documented in Tgmice
from the highest expresser line (F61270). The depletion of CD4+
T cells resulted in an alteration of CD4/CD8 cell ratio (Fig. 3B,
Table 3). This CD4+ T cell depletion was stable during the life
span of the animals and did not increase with time. No change
relative to control non-Tg mice was observed with the other T
cell markers (Thy1.2, TcRah) tested in NefRD35/36AA and
NefD174K Tg mice. Also, the percentages of B cells and
macrophages were similar in both groups (Table 3).
These results indicated that the RD35/36 and D174 residues
of Nef are critical for mediating the depletion of thymocytes
and important for inducing a substantial loss of peripheral
CD4+ T cells in vivo in Tg mice.
The Nef-mediated enhanced activated/memory-like phenotype
of Tg CD4+ T cells is retained in Nef RD35/36AA and Nef D174K
mutants
We previously reported that the peripheral CD4+ T cells
from NefWt-expressing CD4C/HIV Tg mice have an activated/
memory-like phenotype, expressing CD69 and CD25 cell
surface markers and being CD44High, CD45RBLow and
CD62LLow (Weng et al., 2004). To determine whether a similar
phenotype was retained in NefRD35/36AA or NefD174K-expres-sing Tg CD4+ T cells, a FACS analysis was performed to assess
these cell surface markers. As shown (Fig. 4), CD4+ T cells
from CD4C/HIV-NefRD35/36AA Tg mice showed an activated
phenotype, although less pronounced than that induced by
NefWt. Similarly, CD4+ T cells from CD4C/HIV-NefD174K Tg
mice expressed lower levels of CD45RB and CD62L cell
surface markers, associated with an activated/memory pheno-
type. However, other markers of activation (CD69, CD25 and
CD44) were expressed on NefD174K Tg CD4+ T cells at levels
comparable to that on non-Tg CD4+ T cells. These results
indicate that the RD35/36AA and D174A mutations of Nef
have retained this function of NefWt in vivo: its capacity to
activate peripheral CD4+ T cells.
The Nef-mediated reduction of in vitro CD4+ Tcell proliferation
is retained by the Nef RD35/36AA and Nef D174K mutants
We have previously reported that peripheral CD4+ T cells
from NefWt-expressing CD4C/HIV Tg mice show a reduced
cell division in vitro upon stimulation with anti-CD3 + anti-
CD28 or anti-CD3 + IL-2 (Weng et al., 2004). To examine the
proliferative capacity of NefRD35/36AA or NefD174K-expressing
Tg CD4+ T cells in vitro, peripheral LN cells were labeled
with CFSE and FACS profiles were obtained by gating on the
CD4+ T cell population. This analysis showed that upon in
vitro stimulation with anti-CD3 mAb, the majority (60%) of
non-Tg CD4+ divided five to six times (M5 + M6), while a
lower proportion (30%) of Nef RD35/36AA and NefD174K-
expressing Tg CD4+ T cells achieved such divisions (Fig. 5).
In addition, a higher proportion of NefRD35/36AA and NefD174K
(16%) -expressing Tg CD4+ T cells did not divide at all or
underwent only one division (M1 + M2), as compared to non-
Tg CD4+ T cells (8%). Although less severe, this impaired
proliferation resembles that obtained with NefWt-expressing
CD4+ T cells, as also documented previously (Weng et al.,
2004). These results indicate that these two mutations fail to
completely abrogate the capacity of Nef to decrease CD4+ T
cell division after in vitro stimulation, thus segregating this
function from that of CD4 downregulation which is impaired.
The Nef-mediated enhanced apoptosis of CD4+ T cells is
abrogated by the RD35/36 and D174K mutations
Our previous analysis has shown that NefWt-expressing
CD4+ T cells from CD4C/HIV Tg mice exhibit enhanced
Fig. 3. Immunophenotypic analysis of thymic and peripheral T lymphocytes from CD4C/HIV-NefRD35/36AA and CD4C/HIV-NefD174K Tg mice. Thymic (A) and
mesenteric LN (B) cells from a representative CD4C/HIV-NefRD35/36AA (F62328) and CD4C/HIV-NefD174K (F61270) Tg mouse and non-Tg littermate were
analyzed by flow cytometry for the expression of CD4, CD8, TcRah and Thy1.2. The percentage of cells found in each quadrant is indicated. A dotted line was
drawn across to visualize the downregulation of the CD4 cell surface expression.
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Table 2
Analysis of thymic cell surface markers in CD4C/Nefmut Tg mice
Mouse linea Cell number in different subpopulations (106) CD4/CD8 ratio Mean fluorescence (%)b
Thy 1.2 CD4+CD8+ CD4+CD8 CD4CD8+ TcR CD4 CD8
CD4C/NefWt 19.3 T 4.2c 16.9 T 4.4c 1.5 T 0.6c 1.6 T 1.2c 2.6 T 1.7c 0.9 T 0.1c 31.9 T 10.5c 41.1 T 8.9c
CD4C/NefD174K
Non-Tgd 109.8 T 18.6 100 T 17.0 10.0 T 2.3 3.4 T 1.6 14.6 T 2.9 4.3 T 2.4 100 100
F61270 91.7 T 17.2 79.5 T 15.0 9.8 T 1.4 2.1 T 0.3 13.7 T 3.4 3.6 T 1.2 100.1 T 8.1 99.1 T 7.3
F81526 92.6 T 18.9 81.5 T 18.0 8.4 T 1.0 1.9 T 0.3 11.6 T 1.5 3.7 T 1.1 103.0 T 16.0 100.0 T 9.6
F81527 87.1 T 14.8 77.0 T 13.5 7.4 T 1.2 2.1 T 0.2 11.5 T 1.6 3.6 T 1.0 103.0 T 9.7 99.9 T 7.8
CD4C/NefRD35AA
Non-Tgd 82.1 T 11.7 75.4 T 11.0 7.2 T 0.9 1.9 T 0.3 10.8 T 0.9 3.1 T 0.9 100 100
F62327 77.8 T 3.9 68.3 T 4.5 7.2 T 0.7 2.2 T 0.3 11.3 T 0.7 2.8 T 0.8 77.6 T 13.5 99.5 T 19.4
F62328 96.4 T 12.2 84.9 T 11.8 11.5 T 4.2 2.4 T 0.3 14.9 T 1.6 2.3 T 1.0 81.8 T 17.4 93.0 T 28.0
a FACS analysis was performed on at least nine mice (3–9 month-old) for each Tg line. The positive control CD4C/HIVMutG (NefWt) Tg mice were 3–6-month-old.
b The mean fluorescence intensity for CD8 and CD4 was obtained by calculating the ratio of CD4 or CD8 staining in Tg thymuses relative to that of non-Tg
thymuses (100%). Mean values were then calculated with the values for each line.
c P < 0.05 by using Student’s t test.
d The non-Tg control values were obtained by pooling the results of all non-Tg littermates from different lines.
Z. Hanna et al. / Virology 346 (2006) 40–52 47apoptosis/cell death (Priceputu et al., 2005). A similar FACS
analysis of LN CD4+ T cells ex vivo, with 7-AAD staining,
revealed no difference in apoptosis/death of NefRD35/36AA or
NefD174K-expressing CD4+ T cells relative to non-Tg CD4+ T
cells (data not shown). It thus appears that both mutations
significantly affect this Nef function.
Discussion
Nef is a key factor of both HIV and SIV pathogenesis
(reviewed in Fackler and Baur, 2002; Skowronski et al., 1999;
Wei et al., 2003). Although many in vitro functions have been
described for Nef, it has been difficult to determine which of
these functions contribute to its in vivo pathogenicity (Wei et
al., 2003). In the present work, we used the CD4C/HIV Tg
mouse model, in which the development of an AIDS-like
disease is largely dependent on the expression of Nef and
independent of virus replication, to study Nef functions. The in
vivo pathogenicity and the impact of two mutants of Nef
(NefRD35/36AA and NefD174K) on several parameters of theTable 3
Analysis of cell surface markers from splenocytes of CD4C/Nefmut Tg mice
Mouse linea Cell number in different cell populations (106)
Thy 1.2 CD4+ CD8+ B220
CD4C/NefWt 17.1 T 4.1c 9.1 T 1.7c 5.3 T 1.2c 39.3 T 8.5
CD4C/NefD174K
Non-Tgd 27.8 T 4.0 17.2 T 2.1 9.5 T 1.4 60.8 T 13.5
F61270 19.2 T 4.3 9.4 T 2.2c 7.6 T 2.0 77.8 T 25.2
F81526 24.4 T 4.1 14.8 T 2.9 8.5 T 1.6 56.4 T 17.7
F81527 23.3 T 6.6 14.2 T 3.6 8.7 T 2.9 51.6 T 18.5
CD4C/NefRD35AA
Non-Tgd 24.2 T 9.6 18.5 T 6.4 7.1 T 2.1 55.7 T 35.7
F62327 22.4 T 8.6 13.3 T 5.7c 8.8 T 2.8 54.1 T 20.5
F62328 22.8 T 10.4 12.0 T 6.7c 10.3 T 4.4 51.7 T 38.1
a FACS analysis was performed on at least nine mice (3–9 month-old) for each
b The mean fluorescence for CD8 and CD4 were obtained by calculating the ratio o
(100%). Mean values were then calculated with the values for each line.
c P < 0.05 by using Student’s t test.
d The non-Tg control values were obtained by pooling the results of all non-Tg lAIDS-like disease were assessed in this biological system.
These mutations have previously reported to be defective in
downregulating the human CD4 cell surface molecule (Aiken
et al., 1996; Janvier et al., 2001; Stoddart et al., 2003;
Greenberg et al., 1997; Iafrate et al., 1997; Mangasarian et
al., 1999; Lundquist et al., 2002). We first showed that these
mutations also abrogate the Nef-induced downregulation of the
murine CD4 molecule, indicating that the murine effectors of
this pathway are as sensitive as the human effectors to the
RD35/36AA and D174K mutations. These results extend
previous data (Skowronski et al., 1993; Garcia and Miller,
1991) and suggest that these effectors may be common in these
two species and that the molecular pathways of Nef-induced
downregulation of human and murine CD4 may be conserved.
Second, we found that these mutations had a major negative
impact on the pathogenicity of Nef for T cells. Both mutations
prevented the depletion of double-positive CD4+CD8+ and of
single-positive CD4+ and CD8+ thymocytes almost completely
and reduced the loss of peripheral CD4+ T cells, as compared to
that induced by NefWt. The fact that some loss of peripheralCD4/CD8 ratio Mean fluorescence (%)b
TcR Mac-1 CD4 CD8
15.1 T 4.2c 11.6 T 3.9 1.1 T 0.1c 38.9 T 8.4c 96.1 T 6.8
29.3 T 4.0 6.4 T 3.6 1.8 T 0.2 100 100
22.4 T 4.8 10.8 T 3.1 1.2 T 0.6c 87.9 T 10.8 93.1 T 8.3
25.7 T 5.3 6.6 T 5.1 1.8 T 0.3 96.8 T 4.3 97.8 T 4.7
26.0 T 7.5 10.1 T 6.5 1.8 T 0.4 97.7 T 3.7 98.0 T 5.5
26.7 T 8.9 8.7 T 3.3 2.4 T 1.2 100 100
21.4 T 6.4 10.5 T 4.1 1.2 T 0.4c 78.5 T 8.8 89.5 T 12.2
24.4 T 7.1 10.0 T 3.4 1.2 T 0.7c 81.6 T 12.4 99.4 T 10.1
Tg line.
f CD4 or CD8 staining in Tg splenocytes relative to that of non-Tg splenocytes
ittermates from different lines.
Table 4
Cell number in lymphoid organs of control and CD4C/Nefmut Tg mice
Mouse linea Number of cells (106)/organ
Thymus Spleen Mes. lymph
nodes
CD4C/HIVMutG 20.2 T 8.5b 58.2 T 19.3b 6.9 T 4.1b
CD4C/NefD174K
Non-Tgc 117.2 T 19.1 102.1 T 19.0 22.9 T 11.5
F61270 98.3 T 16.9 107.8 T 31.1 18.8 T 5.1
F81526 94.5 T 18.9 95.4 T 27.1 20.4 T 9.9
F81527 89.9 T 15.1 92.3 T 35.4 21.3 T 5.5
CD4C/NefRD35AA
Non-Tgc 92.1 T 30.1 93.9 T 58.3 24.0 T 9.2
F62327 76.3 T 25.0 94.6 T 44.4 23.4 T 10.0
F62328 98.7 T 36.1 91.1 T 57.2 25.4 T 10.1
a A minimum of nine mice (3–9 month-old) of each founder line were
analyzed.
b P < 0.05 by using Student’s t test.
c The non-Tg control values were obtained by pooling the results of all the
non-Tg littermates from different lines.
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NefD174K Tg mice suggests that the downregulation of the CD4
cell surface molecule is not an absolute requirement for
peripheral CD4+ T cell loss in an in vivo context, and that these
two phenotypes can segregate independently. A similar conclu-
sion was reached previously by us, while studying Tg mice
expressing the NefD25–35 mutant (Hanna et al., 2004). Others
also found that the CD4 downregulation function of HIV-1 Nef
could be dissociated in vitro from its other functions, notably its
viral infectivity enhancing function (Foster et al., 2001;
Goldsmith et al., 1995), its CD3 signaling inhibitory functionFig. 4. Analysis of the activated/memory-like immunophenotype of LN CD4+ T cells
FACS analysis of LN CD4+ T cells. Expression of CD69, CD25, CD44, CD45RB
Isotype control antibodies were used as negative controls. The histogram represents t
cell surface marker. The gate was made on positive CD25, CD44 and CD69 cells an
adjusted to 1 for each experiment. Data pooled from three experiments with non-Tg
CD4C/HIV-NefD174K (n = 9, black bars) (F61270) Tg mice. The data were analyze
0.01, (***) P < 0.001.(Iafrate et al., 1997) and its MHC class I downregulation
function (Foster et al., 2001; Mangasarian et al., 1999; Lock et
al., 1999; Swigut et al., 2000). Moreover, the differential
susceptibility to depletion of thymic and peripheral CD4+ T
cells induced by NefRD35/36AA and NefD174K mutants seen here
and by the NefG2A and NefD25–35 mutants observed before
(Hanna et al., 2004) is likely to be a function of Nef which is
independent of its inability to downregulate CD4, since NefG2A
was quite efficient at downregulating CD4. Interestingly, our
data show that the NefRD35/36AA and NefD174K mutants have
partially retained their ability to activate murine peripheral CD4+
T cells and to decrease their in vitro response upon stimulation
through the TcR. These findings in murine cells extend previous
work in human cells showing that these two Nef mutants had
retained these two functions in Jurkat cells (Iafrate et al., 1997).
These results also suggest that these two latter Nef functions
observed in murine peripheral CD4+ Tcells have little impact on
the number and distribution of thymic T cells which appear
normal in NefRD35/36AA and NefD174K-expressing Tg mice. In
addition, these results suggest that CD4 downregulation is
not necessarily linked in vivo to the Nef-induced activation
phenotype of CD4+ T cells. Therefore, the differential
susceptibility of thymic and peripheral CD4+ T cells to the
NefRD35/36AA and NefD174K-induced depletion is consistent
with the notion that distinct and independent mechanisms
may be involved in the loss of the thymic and peripheral
CD4+ T cell populations, following Nef expression.
The relative resistance of T cells expressing these Nef
mutants to depletion corroborates previous results on the SIV
NefD204R (residue D204 equivalent to residue D174 of HIVNL4-3from CD4C/HIV-NefRD35/36AA and CD4C/HIV-NefD174K Tg mice. Three-color
and CD62L molecules on the surface of CD4+ TcRah+ T cells was measured.
he ratio (Tg/non-Tg) of the percentage of CD4+ T cells expressing the indicated
d on cells expressing low levels of CD62L and CD45RB. Non-Tg values were
(n = 7, white bars) and CD4/HIV-NefRD35/36AA (n = 6, grey bars) (F62328) and
d by the Student’s t test, comparing Tg versus non-Tg. (*) P < 0.05, (**) P <
Fig. 5. Reduced division of CD4+ T cells from CD4C/HIV-NefRD35/36AA and CD4C/HIV-NefD174K Tg mice in response to anti-CD3 stimulation in vitro. Single cell
suspensions were prepared from peripheral LNs and labeled by CFSE. After 3 days of culture with anti-CD3, the cells were harvested and stained with CD4-PE mAb
and 7-AAD to gate on live (7-AAD-negative) cells. Histograms representing the percentages (mean T SEM) of CD4+ T cells in the indicated generations (m) upon in
vitro stimulation for 3 days. Data were pooled from two independent experiments with cells from NefRD35/36AA (n = 6, grey bars) (F62328) and NefD174K (n = 6,
black bars) (F61270) Tg mice, as well as from non-Tg mice (n = 7, white bars). Cells from CD4C/HIVMutG (NefWt, F27367) Tg mice (n = 7, strippled bars) were
used as positive controls for impaired division in vitro. The data were analyzed by the Student’s t test: (*) P < 0.05; (**) P < 0.01; (***) P < 0.001.
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pathogenic, respectively, in SIV-infected macaques (Iafrate
et al., 2000) and in SCID-hu Thy/Liv mice (Stoddart et
al., 2003), although the low virulence documented in both
models could be accounted for by the reduced viral load. In
addition, other, but not all (Michael et al., 1995) studies have
reported an apparent correlation between CD4 downregulation
and T cell loss in SIV-infected macaques or HIV-infected
individuals. Pathogenic SIV variants from late infection
showing enhanced infectivity were more effective at down-
regulating CD4 than those obtained during early infection
(Patel et al., 2002). Nef alleles from LTNP or asymptomatic/
slow progressers HIV-infected individuals were also found to
have a decreased ability to downregulate CD4 as compared to
those from progressors (Glushakova et al., 2001; Tobiume et
al., 2002; Carl et al., 2001; Arganaraz et al., 2003; Casartelli et
al., 2003; Mariani et al., 1996). Much of these effects could
be correlated with a lower ability of the alleles showing
poor CD4 downregulation to stimulate virus production.
However, in all these studies, the effect of the mutation on
virus replication itself could not be distinguished from its
role in T cell homeostasis and metabolism. The Tg approach
used here have extended these results and provided a tool to
determine that these two mutations can abrogate the Nef-
induced loss of both thymic and, to a large extent,
peripheral CD4+ T cells, independently of their other effects
on virus replication.Finally, our data show differential outcome of the Nef
mutations on the multiple organ pathologies, which normally
develop in the CD4C/HIV Tg mice expressing NefWt. We found
that NefRD35/36AA-expressing Tgmice did not develop such organ
diseases, a result similar to that obtained previously with the
NefD25–35-expressing Tg mice (absence of downregulation of
CD4 and no organ disease) (Hanna et al., 2004). In contrast, the
NefD174K Tg mice developed organ diseases, although milder
than that induced by NefWt, especially when levels of expression
are taken into account. Indeed, Tg mice (F81527) expressing
NefD174K only slightly less (0.5-fold) relative to NefWT (F27367)
did not show any sign of disease. We reported previously that Tg
mice expressing similar low levels of NefWt (F27372, F27011)
developed a typical AIDS-like disease (Hanna et al., 1998b).
Also, Tg mice (F61270) expressing NefD174K at much higher
levels (5) than NefWT (F27367) showed typical pathological
changes observed in NefWt Tg mice, but survived much longer.
We showed before that such high levels ofNefWTexpression inTg
mice led to death very early in life (within one month) (Hanna et
al., 1998b). These combined results indicate that the CD4
downregulation itself is not linked to the development of the
organ diseases and that these two phenotypes can segregate
independently. Such a segregation was somewhat anticipated,
since we previously showed that the development of organ
diseases is independent of the T cell loss (Hanna et al., 2004) and
can occur in the absence of CD4+ Tcells (on which CD4 downre-
gulation occurs) inCD4-deficientNefWtTgmice (Weng et al., 2004).
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[NefD174K, NefRD35/36AA (this study), NefD25–35 and NefD57–
66 (Hanna et al., 2004)] mutated in different motifs, which have
lost the ability to downregulate CD4 completely or very
significantly. In all these mutant Tg lines, absence of CD4
downregulation was associated with attenuated organ disease
known to occur independently of the presence of CD4+ T cells
(Weng et al., 2004). This strongly suggests that these mutations
affect other functions of Nef independently of the CD4
downregulation itself. These in vivo findings contrast with
other in vitro studies showing that the NefRD35/36AA and
NefD174K mutants only impaired the ability of Nef to down-
regulate CD4 without affecting other Nef functions (Manga-
sarian et al., 1999; Stoddart et al., 2003; Lundquist et al., 2002;
Aiken et al., 1996; Iafrate et al., 1997). These in vivo studies
have revealed additional functions of Nef that affect its
pathogenesis, and that were not predicted by in vitro work.
Therefore, in a clinical setting, the lower ability of Nef to
downregulate CD4 observed in LTNP and in asymptomatic/
slow progressers HIV-1 or SIV-infected carriers (Tobiume et
al., 2002; Patel et al., 2002; Arganaraz et al., 2003; Carl et al.,
2001; Casartelli et al., 2003; Mariani et al., 1996) may
represent a surrogate marker, not only associated with poor
virus production and infectivity, as extensively documented
(Cortes et al., 2002; Ross et al., 1999; Lama et al., 1999;
Lundquist et al., 2002; Glushakova et al., 2001; Tanaka et al.,
2003; Arganaraz et al., 2003), but also apparently reflecting a
poor intrinsic pathogenicity of the Nef molecule, independently
of its effect on virus replication. If the data presented here in Tg
mice reflect the behavior of this molecule in HIV-infected
individuals, the loss of CD4 downregulation reported in LTNP
or in asymptomatic/slow progresser HIV-infected carriers may
indicate the presence of Nef variants defective in not only CD4
downregulation, but also in other important functions involved
in their virulence and which may even be different from those
regulating virus production.
Materials and methods
Mice
The CD4C/HIVMuG transgene used in these experiments has
been described previously (Hanna et al., 1998b). These Tg
mice harbor a complete HIV-1NL4-3 genome in which all the
known open reading frames (ORF), except that of Nef, have
been interrupted by mutations. Only the wild-type Nef protein
(NefWt) is expressed in these Tg mice. The CD4C/HIV-
NefRD35/36AA and CD4C/HIV-NefD174K were generated as
previously described (Hanna et al., 1998a, 1998b). The
arginine/aspartic acid residues at position 35/36 and the
aspartic acid at position 174 of the HIV-1NL4-3 Nef protein
were mutated to AA35/36 and K174, respectively. These
mutations were produced using PCR site-directed mutagenesis
on a SacI–BamHI HIV-1 fragment subcloned in the pBS KS
vector as described previously (Hanna et al., 2001b, 2004)
using mutational primers # 625 (CTAGGGCTGCAGA-
TACTGCTCC) containing GCTGC replacing TCTGG at nts8889–8893, to produce the NefRD35/36AA mutation and primer
#610 (CTCAGGGTCCTTCATTCCATG), containing CTT,
replacing ATC at nts 9306–9308, to produce the NefD174K
mutation. Mutations were then confirmed by sequencing and
the SacI–BamHI fragment was ligated with the transgene
CD4C/HIVMutG backbone, thus replacing NefWt (Fig. 1). Each
linearized transgene was purified and injected into 1-day-old
(C57BL/6 X C3H)F2 embryos to generate Tg mice as
described (Hanna et al., 1998a, 1998b, 2001b, 2004). The Tg
lines were maintained by breeding on the C3H background.
Transgene expression
The levels of transgene expression were measured by
Northern and Western blot analysis, as previously described
(Hanna et al., 1998a, 1998b, 2001b, 2004). Production of
rabbit anti-Nef antibodies was described previously (Hanna et
al., 2001b). Mice expressing mutant Nef at an equal or higher
level than that of NefWt were kept and bred for further analysis,
while those founders expressing Nef at lower levels were
discarded. In addition, evaluation of transgene expression in
peripheral organs was carried out by RT-PCR on RNA isolated
from sorted CD4+ T cells. Primers used for detecting HIV
transcripts were oligos #77 (CCCCACTGGGCTCCTGGTTG-
CAGC), located in exon 1 of the human CD4 gene and oligo
#988 (CAGTCGCCGCCCCTCGCCTCTT), specific for the
HIV genome, respectively. Expression of HPRTwas used as an
internal control using primers # 1227 and 1228 (GTTGGATA-
CAGGCCAGACTTTGTTG) and (GATTCA ACTTGCGCT-
CATCTTAGGC), respectively.
Histological analysis
Histological assessment on lymphoid and nonlymphoid
organs was carried out essentially as previously described
(Hanna et al., 1998a, 1998b). Semiquantitative analysis was
performed on lungs and kidney sections using a scale from 1 to
4. The criteria for lung disease (lymphocytic and monocyte
infiltration in the interstitium) were the following. The score 1
was given to lung showing 1 to 2 patched areas (field at 20),
with or without infiltration around bronchioles or vessels; 2, for
>3 patches to 50% of surface area involved; 3, for >50%
surface area involved; 4, for uniform infiltration or consolida-
tion in whole surface area. The criteria for nephropathy (FSGS
and tubolo-interstitial nephritis with microcystic dilation) were
the following. The score 1 was given to diseased kidney with
1–5 glomeruli affected with their tubules; 2, for 10–50%
surface area affected; 3, for >50% surface area affected and 4,
for almost all nephrons affected.
The individual scores were added up and divided by total
number of mice analyzed to obtain the average score.
Flow cytometry analysis
Flow cytometry was performed on a FACScan and FACS
Calibur (Becton Dickinson, San Jose, CA), using antibodies
against various cell surface markers: CD4, CD8, TcRah and
Z. Hanna et al. / Virology 346 (2006) 40–52 51Thy1.2 for T cells and B220, Mac-1 for B cells and
macrophages, respectively, as described previously (Hanna et
al., 1998a, 1998b; Weng et al., 2004). Also, staining of CD25,
CD44, CD69, CD45RB and CD62L was used to measure
activation markers.
CFSE fluorescent dye cell labeling
CFSE (5- and 6-Carboxyfluorescein Diacetate Succinimidyl
Ester) (Molecular Probes Inc; Eugene, Oregon) labeling was
performed as previously described (Hanna et al., 2004; Weng et
al., 2004), on total LN cells.
Statistics
Statistical analyses (ANOVA, Sigmastat and Student’s t test)
were performed as previously described (Weng et al., 2004;
Hanna et al., 2001b).
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